Develops therapies made from patients’ modified immune cells for people with light-chain amyloidosis and other serious diseases.
10-K for FY2025, filed Mar 25, 2026
No revenue reported yet.
10-K for FY2025, filed Mar 25, 2026
Portfolio focus
The older report described tissue-targeted drug programs for solid tumors and inflammation alongside a separate cell-therapy unit; the latest centers on CAR-T for AL amyloidosis and other serious diseases.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 25, 2026Immix Biopharma, Inc. has the following two business units:View ↗
ImmixBio. ImmixBio is focused on developing Tissue Specific Therapeutics targeting solid tumors and immune-dysregulated diseases. As of…View ↗
We are a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics (“TSTx”)TM in oncology and…View ↗
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy…View ↗
Competes with Abbvie, Caelum Biosciences, Alexion, AstraZeneca, Janssen, and Johnson & Johnson
10-K for FY2025, filed Mar 25, 2026We currently face and will continue to face competition for our development programs from groups that are developing therapies for oncology…View ↗
Loading...